Market Place
Sourcing Support
Novartis Twice-Yearly Leqvio Demonstrated Clinically Meaningful LDL-C Lowering
28 Aug 2024 //
GLOBENEWSWIRE
EnPlusOne Achieves Enzymatic Synthesis Of Leqvio Antisense Strand
09 Jul 2024 //
BUSINESSWIRE
Novartis tops docs` ranking of heart disease drug makers
08 May 2024 //
FIERCE PHARMA
Novartis Shows Data of Leqvio Significantly Reduces LDL-C in ASCVD Patients
06 Apr 2024 //
GLOBENEWSWIRE
?Novartis presents new long-term Leqvio® (inclisiran) data efficacy and safety
28 Aug 2023 //
PR NEWSWIRE
siRNA therapy shows long-term potential in lowering LDL-C
28 Aug 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
FDA Approves Expanded Indication for Leqvio
11 Jul 2023 //
PR NEWSWIRE
Novartis scraps UK heart attack prevention trial
23 Mar 2023 //
REUTERS
New long-term Leqvio® data from Novartis show sustained efficacy and safety
07 Nov 2022 //
GLOBENEWSWIRE
Soleo Selected as Limited Drug Distribution Partner for Administration of LEQVIO
01 Aug 2022 //
BUSINESSWIRE
Novartis` Leqvio poised to rake in $2.5B, overtake competition
23 Feb 2022 //
FIERCEPHARMA
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
23 Dec 2021 //
BIOPHARMADIVE
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA
22 Dec 2021 //
GLOBENEWSWIRE
Alnylam Comments on FDA Approval of Leqvio
22 Dec 2021 //
BUSINESSWIRE
Analyst puts Amgen`s Otezla, Repatha, biosimilars on notice
23 Nov 2021 //
FIERCEPHARMA
Novartis weighs Alnylam buy with Roche stake sale cash: report
19 Nov 2021 //
FIERCEPHARMA
Novartis touts more late-stage data for inclisiran
12 Nov 2021 //
ENDPTS
Alnylam Pharmaceuticals Reports Q3 2021 Financial Results and Highlights
28 Oct 2021 //
BUSINESSWIRE
SEC refuses local trial waiver for Novartis’ inclisiran injection
26 Oct 2021 //
PHARMABIZ
NICE approves inclisiran for LDL cholesterol reduction
01 Sep 2021 //
EUROPEAN PHARMACEUTICAL REVIEW
Inclisiran added to a new section of the Drug Tariff (Part VIIIC) : PSNC
27 Aug 2021 //
PSNC
Should Novartis worry about ICER`s price range for inclisiran?
30 Jan 2021 //
FIERCE PHARMA
Pricing challenge looms for Novartis as cholesterol drug`s US fate remains
26 Jan 2021 //
BIOPHARMADIVE
Novartis unsure when FDA might OK its once-rejected inclisiran
25 Jan 2021 //
FIERCE PHARMA
Novartis’ $9.7B PCSK9 drug nabs first OK now comes challenge of finding a market
12 Dec 2020 //
ENDPTS
Novartis` blockbuster-to-be inclisiran snags first nod in EU
11 Dec 2020 //
FIERCEPHARMA
Novartis gets EU approval for potential blockbuster cholesterol drug Leqvio
11 Dec 2020 //
REUTERS
Novartis sees EU OK ahead after panel nod for $10 bln anti-cholesterol prospect
17 Oct 2020 //
REUTERS
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran)
16 Oct 2020 //
NOVARTIS
Novetis`s new analysis shows inclisiran consistency in LDL-C reduction
31 Aug 2020 //
ENDPTS
Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha
31 Aug 2020 //
FIERCE PHARMA
Novartis new analysis shows high consistency in lowering LDL-C
30 Aug 2020 //
PRNEWSWIRE
ICER to Assess Treatments for High Cholesterol
12 Jun 2020 //
ICER
Novartis` cholesterol buster, new trials fall victim to COVID-19
29 Apr 2020 //
FIERCE BIOTECH
Novartis presents pooled inclisiran data cutting LDL by 51%
30 Mar 2020 //
FIERCE BIOTECH
Novartis announces NEJM publication of three pivotal trials showing durable
18 Mar 2020 //
PRNEWSWIRE
Novartis picks up inclisiran after completion of MedCo acquisition
08 Jan 2020 //
PM LIVE
The Medicines Company to Present Inclisiran Data ORION-9 & ORION-10 Pivotal Ph3
06 Nov 2019 //
BUSINESSWIRE
Medicines Company`s cholesterol buster poised for PCSK9 battle
26 Sep 2019 //
FIERCE BIOTECH
The Medicines Comp`s Inclisiran Treats Cholesterol, No Liver,Renal Side effects
26 Sep 2019 //
BIOSPACE
MedCo builds its case for star cholesterol RNAi therapy
25 Sep 2019 //
ENDPTS
Clean data tee Medicines Company up for PCSK9 scrap
03 Sep 2019 //
FIERCE BIOTECH
U.S. District Court Invalidates Amgen Patents Over Cholesterol Med
30 Aug 2019 //
BIOSPACE
Praluent, Repatha face major new PCSK9 threat
27 Aug 2019 //
FIERCE PHARMA
Medicines Co.`s PCSK9 drug succeeds in first Phase 3 test
27 Aug 2019 //
BIOPHARMADIVE
Analysis shows The Medicines Company/Alnylam drug inclisiran safe
28 May 2019 //
ENDPTS
Med Co, Alnylam`s inclisiran cuts cholesterol long-term
21 May 2019 //
FIERCE BIOTECH
